Old Web
English
Sign In
Acemap
>
authorDetail
>
Bifeng Ding
Bifeng Ding
Amgen
Oncology
Internal medicine
Carfilzomib
Daratumumab
Medicine
4
Papers
13
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial
2021
International Journal of Hematology
Kenshi Suzuki
Chang-Ki Min
Ki-Hyun Kim
Je-Jung Lee
Hirohiko Shibayama
Po-Shen Ko
Shang-Yi Huang
Sin-Syue Li
Bifeng Ding
Monica Khurana
Shinsuke Iida
Show All
Source
Cite
Save
Citations (0)
Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma.
2021
Leukemia & Lymphoma
David S. Siegel
Katja Weisel
Anita Zahlten-Kumeli
Rohan Medhekar
Bifeng Ding
Xavier Leleu
Show All
Source
Cite
Save
Citations (0)
Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study
2020
Blood
Meletios A. Dimopoulos
Hang Quach
Maria-Victoria Mateos
Ola Landgren
Xavier Leleu
David S. Siegel
Katja Weisel
Maria Gavriatopoulou
Albert Oriol
Neil Rabin
Ajay K. Nooka
Ming Qi
Bifeng Ding
Anita Zahlten-Kumeli
Saad Z. Usmani
Show All
Source
Cite
Save
Citations (13)
Health related quality of life (HRQoL) outcomes from the phase III CANDOR study comparing carfilzomib, dexamethasone, and daratumumab (KdD) to carfilzomib and dexamethasone (Kd) in patients (Pts) with relapsed or refractory multiple myeloma.
2020
Journal of Clinical Oncology
David S. Siegel
Katja Weisel
Anita Zahlten-Kumeli
Rohan Medhekar
Sandhya Sapra
Bifeng Ding
Xavier Leleu
Show All
Source
Cite
Save
Citations (0)
1